<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00869336</url>
  </required_header>
  <id_info>
    <org_study_id>TP-0801</org_study_id>
    <nct_id>NCT00869336</nct_id>
  </id_info>
  <brief_title>Multicenter Study of the Efficacy and Safety of Luliconazole Cream in Tinea Pedis (Athlete's Foot)</brief_title>
  <official_title>Phase 2 Study - A Randomized, Multi-Center, Double-Blind, Placebo-Controlled Duration Finding Study Evaluating the Efficacy and Safety of Two Week and Four Week Once Daily Treatment of Luliconazole Cream 1% in Patients With Tinea Pedis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tinea Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tinea Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To examine the safety and optimal duration of Luliconazole Cream 1% treatments for 14 days or
      28 days to achieve &quot;complete clearance&quot; at 2 weeks post treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects who achieve complete clearance at 2 weeks post treatment</measure>
    <time_frame>Two weeks post treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who achieve effective treatment at 2 and 4 weeks post treatment</measure>
    <time_frame>2 and 4 weeks post treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">147</enrollment>
  <condition>Tinea Pedis</condition>
  <arm_group>
    <arm_group_label>Luliconazole Cream 1% - 2 wks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily treatment with Luliconazole Cream 1% for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Luliconazole Cream 1% - 4 wks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily treatment with Luliconazole Cream 1% for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Comparator - 2 wks</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Daily treatment with Vehicle Cream for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Comparator - 4 wks</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Daily treatment with Vehicle Cream for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Luliconazole Cream 1% - 2 wks</intervention_name>
    <description>Topical cream applied daily for 2 weeks</description>
    <arm_group_label>Luliconazole Cream 1% - 2 wks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Comparator -2 wks</intervention_name>
    <description>Placebo cream applied daily for 2 weeks</description>
    <arm_group_label>Placebo Comparator - 2 wks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Luliconazole Cream 1% - 4 wks</intervention_name>
    <description>Topical cream applied daily for 4 weeks</description>
    <arm_group_label>Luliconazole Cream 1% - 4 wks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Comparator - 4 wks</intervention_name>
    <description>Placebo cream applied daily for 4 weeks</description>
    <arm_group_label>Placebo Comparator - 4 wks</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects of either gender must be 12 years of age or older.

          2. Subjects with a clinical diagnosis of interdigital tinea pedis on one or both feet
             characterized by clinical evidence of a tinea infection (at least moderate erythema,
             moderate scaling, and mild pruritus) based on signs and symptoms.

          3. Subjects with a mycological diagnosis of interdigital tinea pedis confirmed by the
             detection of fungal hyphae on a microscopic KOH wet mount

          4. Females of child-bearing potential must have a negative urine pregnancy test and must
             agree to use an effective form of contraception

        Exclusion Criteria:

          1. Subjects with moccasin (dry type) tinea pedis; with concomitant onychomycosis of the
             fingernails and/or toenails on the evaluated foot, with severe dermatophytoses, a
             concurrent tinea infection or bacterial skin infection on the evaluated foot;

          2. Female subjects who are pregnant and/or nursing or planning a pregnancy during the
             course of the trial.

          3. Subjects who are immunocompromised (due to disease, e.g., HIV or medications

          4. Subjects with a history of intolerance or hypersensitivity to imidazole compounds or
             the inactive components of the cream;

          5. Subjects with a life-threatening condition (e.g., autoimmune deficiency syndrome,
             cancer, unstable angina, or myocardial infarction) within the last 6 months.

          6. Subjects using the following medications:

               1. topical antifungal agent within 30 days of the baseline visit

               2. systemic antifungals within 8 weeks of the baseline visit (8 months for oral
                  terbinafine)

               3. topical corticosteroid in treatment area(s) within 30 days of the baseline visit.

               4. systemic corticosteroids within 30 days of the baseline visit;

               5. any other topical medicated topical treatments to the treatment area(s) within 7
                  days of baseline visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>College Station</city>
        <state>Texas</state>
        <zip>77840</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 25, 2009</study_first_submitted>
  <study_first_submitted_qc>March 25, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2009</study_first_posted>
  <disposition_first_submitted>June 6, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>June 6, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 21, 2011</disposition_first_posted>
  <last_update_submitted>June 6, 2011</last_update_submitted>
  <last_update_submitted_qc>June 6, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 21, 2011</last_update_posted>
  <responsible_party>
    <name_title>Tinea Pharmaceuticals, Inc.</name_title>
    <organization>Tinea Pharmaceuticals, Inc.</organization>
  </responsible_party>
  <keyword>Tinea Pedis</keyword>
  <keyword>Athlete's Foot</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tinea</mesh_term>
    <mesh_term>Tinea Pedis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

